文献速递精神分裂症与精神病性障碍

早发精神病和高危状态中单胺氧化酶B(星形胶质细胞标志物)改变的证据

Evidence of altered monoamine oxidase B, an astroglia marker, in early psychosis and high-risk state.
PubMed 文献 · Mol Psychiatry · 2024-11-07

本研究用[11C]SL25.1188 PET测量38名参与者(14例未用药/最低暴露的首发精神病、7例临床高危个体、17名健康志愿者)的脑内MAO-B VT。结果显示组间MAO-B VT存在显著差异,临床高危组较健康志愿者显著降低(Cohen's d=0.99);大麻使用对MAO-B VT有显著影响,且与分组存在交互作用,使用大麻的临床组MAO-B VT更低,纹状体降低较皮层更显著。

要点

  • 临床高危组MAO-B VT较健康志愿者显著降低(Cohen's d=0.99)。
  • 大麻使用对MAO-B VT有显著主效应,且与分组存在显著交互作用。
  • 使用大麻的临床组纹状体MAO-B VT降低较皮层更显著。

核心结论

  • 早发精神病和临床高危个体脑内MAO-B浓度降低,支持星形胶质细胞功能障碍。
  • 使用大麻的临床高危和首发精神病患者MAO-B浓度降低。
  • MAO-B降低与精神病中纹状体多巴胺升高及精神分裂症星形胶质细胞功能障碍一致。

研究设计与样本

  • 38名参与者接受90分钟[11C]SL25.1188 PET扫描测量MAO-B VT。
  • 参与者包括14例首发精神病(平均[SD]年龄25.7[5.7]岁;6名女性)、7例临床高危(平均[SD]年龄20.9[3.7]岁;4名女性)和17名健康志愿者(平均[SD]年龄31.2[13.9]岁;9名女性)。
  • 首发精神病参与者未用药或最低暴露;尿药筛阳性者排除(大麻除外)。

主要发现

  • 控制烟草使用(F(1,37.42)=5.37,p=0.03)和大麻使用(F(1,37.42)=5.11,p=0.03)后,组间区域MAO-B VT存在显著差异(F(2,37.42)=4.56,p=0.02,Cohen's f=0.49)。
  • 临床高危组MAO-B VT较健康志愿者显著降低(Cohen's d=0.99)。
  • 大麻使用对MAO-B VT有显著效应(F(1,39.19)=12.57,p=0.001,Cohen's f=0.57),且存在显著分组×大麻交互作用(F(2,37.30)=3.82,p=0.03,Cohen's f=0.45),使用大麻的临床组MAO-B VT更低。
  • MAO-B VT降低在纹状体较皮层更显著,见于两个临床组(F(12,46.84)=2.08,p=0.04,Cohen's f=0.73)和大麻使用者(F(6,46.84)=6.42,p<0.001,Cohen's f=0.91)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A novel radiotracer, [11C]SL25.1188, targets monoamine oxidase-B (MAO-B) enzyme, found primarily in astrocytes, which metabolizes monoamines (including dopamine), particularly in subcortical regions. Altered astrocyte function in schizophrenia is supported by convergent evidence from post-mortem, genetic, transcriptomic, peripheral and preclinical findings. We aimed to test whether levels of MAO-B, an index of astrocyte function are low in the living brains of early psychosis and their high-risk states. Thirty-eight participants including antipsychotic-free/minimally exposed clinical participants with first-episode psychosis (FEP), clinical high-risk (CHR) individuals and healthy volunteers (HVs) underwent a 90-min positron emission tomography (PET) scan with [11C]SL25.1188, to measure MAO-B VT, an index of MAO-B concentration. Participants were excluded if tested positive on urine drug screen (except for cannabis). This study of 14 FEP (mean[SD] age, 25.7[5.7] years; 6 F), 7 CHR (mean[SD] age, 20.9[3.7] years; 4 F) and 17 HV (mean[SD] age, 31.2[13.9] years; 9 F) demonstrated significant group differences in regional MAO-B VT (F(2,37.42) = 4.56, p = 0.02, Cohen's f = 0.49), controlling for tobacco (F (1,37.42) = 5.37, p = 0.03) and cannabis use (F(1,37.42) = 5.11, p = 0.03) with significantly lower MAO-B VT in CHR compared to HV (Cohen's d = 0.99). We report a significant cannabis effect on MAO-B VT (F(1,39.19) = 12.57, p = 0.001, Cohen's f = 0.57), with a significant group-by-cannabis interaction (F(2,37.30) = 3.82, p = 0.03, Cohen's f = 0.45), indicating lower MAO-B VT in cannabis-using clinical groups. Lower MAO-B VT levels were more robust in striatal than cortical regions, in both clinical groups (F(12,46.84) = 2.08, p = 0.04, Cohen's f = 0.73) and in cannabis users (F(6,46.84) = 6.42, p < 0.001, Cohen's f = 0.91). Lower MAO-B concentration supports astrocyte dysfunction in cannabis-using CHR and FEP clinical populations. Lower MAO-B is consistent with replicated striatal dopamine elevation in psychosis, as well as astrocyte dysfunction in schizophrenia.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Nisha Aji K, Lalang N, Ramos-Jiménez C, et al. Evidence of altered monoamine oxidase B, an astroglia marker, in early psychosis and high-risk state. Mol Psychiatry. 2024. PMID: 39511452. doi:10.1038/s41380-024-02816-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。